BWAY:NSD-BrainsWay Ltd (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 8.94

Change

+0.54 (+6.43)%

Market Cap

USD 0.14B

Volume

0.08M

Avg Analyst Target

USD 15.20 (+70.02%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

-1.87 (-0.26%)

USD56.71B 124.35 55.99
PODD Insulet Corporation

-1.40 (-0.48%)

USD20.01B 2,208.27 244.52
ABMD Abiomed Inc

-0.25 (-0.07%)

USD15.91B 103.67 53.06
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

-0.29 (-0.34%)

USD12.64B 81.79 28.22
SWAV ShockWave Medical Inc

-5.12 (-2.25%)

USD8.00B N/A N/A
TNDM Tandem Diabetes Care Inc

-1.72 (-1.37%)

USD7.91B 1,218.35 239.94
INMD InMode Ltd

+5.43 (+3.17%)

USD6.53B 57.19 40.15
IART Integra LifeSciences Holdings ..

-0.15 (-0.21%)

USD6.12B 29.96 19.16
LIVN LivaNova PLC

-0.47 (-0.57%)

USD4.37B 77.40 N/A

ETFs Containing BWAY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.57% 52% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.57% 52% F 65% D
Trailing 12 Months  
Capital Gain 53.21% 48% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.21% 48% F 63% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -4.34% 17% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.34% 17% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 27.00% 89% B+ 65% D
Risk Adjusted Return -16.07% 15% F 13% F
Market Capitalization 0.14B 34% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.15 82% B- 58% F
Price / Cash Flow Ratio -97.23 93% A 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -11.66% 64% D 44% F
Return on Invested Capital -23.10% 56% F 27% F
Return on Assets -2.56% 70% C- 38% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.17 94% A 94% A
Short Percent 1.36% 85% B 70% C-
Beta 0.76 73% C 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.